GLP-1 Receptor Agonists
Incretin receptor pharmacology, peptide engineering and analytical characterisation
Overview
Glucagon-like peptide-1 (GLP-1) receptor agonists are peptides, and a few small molecules, that bind and activate the GLP-1 receptor, a class B G-protein-coupled receptor that signals mainly through Gs and cyclic AMP. Several members also engage the GIP, glucagon or amylin receptors. This guide covers how the class is built, how receptor activity is measured in vitro, and how the compounds are characterised analytically.
The Receptor and Its Signalling
Native GLP-1(7-36) amide is a 30-residue peptide. Its N-terminus engages the receptor transmembrane core while the helical C-terminal region binds the extracellular domain, the two-domain binding model common to class B GPCRs. Activation raises intracellular cAMP and recruits beta-arrestin, and in vitro work quantifies this with cAMP accumulation assays, reporter-gene assays and receptor-internalisation imaging in transfected cell lines. Native GLP-1 is cleaved within minutes by dipeptidyl peptidase-4 between residues 8 and 9, which is the property the engineered analogues are designed around.
How the Analogues Are Engineered
Three structural strategies recur. Substitution at position 8 (Aib in GLP-1 SM) removes the DPP-4 cleavage site. Fatty-acid acylation through a linker, as in GLP-1 SM and GLP-2 TZ, gives reversible albumin binding. Exendin-4 scaffolds (exenatide, lixisenatide) start from a naturally DPP-4 resistant sequence. Multi-receptor agonists combine pharmacophores in one chain: GLP-2 TZ is a GIP and GLP-1 receptor agonist, survodutide and mazdutide target the GLP-1 and glucagon receptors, and GLP-3 RT engages GLP-1, GIP and glucagon receptors. Cagrilintide is an acylated amylin analogue rather than a GLP-1 agonist, and orforglipron is a non-peptide small molecule acting at the same receptor.
How These Compounds Are Characterised
Identity is established by mass spectrometry: an intact mass, or a precursor and fragment transition (MRM) matched against a reference standard, confirms that the sequence in the vial is the one on the label. Purity is a chromatographic figure, the principal peak area by reversed-phase HPLC, and it bounds peptide-related impurities only; it says nothing about counterion, water or residual solvent content, which is why net peptide content is reported separately. Lyophilised material is stored cold, dry and dark, and a certificate states what was measured on one named lot. Acylated analogues add specific analytical points: the lipidated side chain shifts retention time markedly, aggregation can appear as broadened or late-eluting peaks, and the intact mass must account for the full linker and fatty-acid moiety, so a mass calculated from the amino acid residues alone will not match.
Reading the Literature
Most of the published literature on this class is clinical, and its endpoints are organism outcomes that a research-use supplier does not restate. For laboratory work the useful sources are the receptor pharmacology papers: binding affinity and functional potency at each receptor, bias between cAMP and beta-arrestin pathways, and structural studies of the peptide-receptor complex. When comparing reported potencies, check the cell line, receptor species and expression level, because EC50 values for the same compound differ across assay systems.
Compounds in this class
GLP-1 SM
- Class:
- GLP-1 receptor agonist
- Formula:
- C187H291N45O59
- Molecular weight:
- ~4113.6 g/mol
GLP-2 TZ
- Class:
- GIP and GLP-1 receptor dual agonist
- Molecular weight:
- ~4813.5 g/mol
GLP-3 RT
- Class:
- GLP-1, GIP and glucagon receptor triple agonist
GLP-1 LR
- Class:
- GLP-1 receptor agonist
- Molecular weight:
- ~3,751 g/mol
GLP-1 DG
- Class:
- GLP-1 receptor agonist
- Molecular weight:
- ~59,670 g/mol (fusion protein)
Exenatide
- Class:
- GLP-1 receptor agonist
- Sequence:
- H-His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-...
- Molecular weight:
- ~4186.6 g/mol
- CAS:
- 141758-74-9
Survodutide
- Class:
- Glucagon and GLP-1 receptor dual agonist
CAGRILINTIDE + GLP-1 SM
- Class:
- Amylin receptor agonist
Mazdutide
- Class:
- GLP-1 and glucagon receptor dual agonist
- Molecular weight:
- ~4233.7 g/mol
Orforglipron
No identity data on file for this compound.
Cotadutide
- Class:
- GLP-1 and glucagon receptor dual agonist
Browse the research catalogue
Buying and verification
Research Use Only. For in-vitro laboratory research by qualified professionals only. Not for human or animal administration. Not a drug, food, cosmetic or dietary supplement. Not intended to diagnose, treat, cure, mitigate or prevent any disease. Volta does not provide dosing, administration or protocol guidance for any material listed.
